Cevira® receives Fierce Innovation Award 2019

Published: 19 December 2019Product AnnouncementsPartnership News & Expansion
**Oslo, Norway December 19, 2019: Photocure ASA (Photocure, PHO: OSE) proudly announces that Cevira® received the prestigious Fierce Innovation Award (FIA), on December 18, 2019.** The Fierce Innovation Awards - LifeSciences Edition is a yearly peer reviewed awards program from the publisher of FierceBiotech and FiercePharma. Winners are named by a jury of experts from the life science industry. Cevira came in first in the Medical Device Innovation category for its innovative design. In this category the Fierce Innovation Award honors the best medical device innovations that have the greatest opportunity to have an impact on the industry. Cevira is a photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade cervical dysplasia. It is easy to use: the drug and device with an automatic timer is placed on the cervix by the gynecologist and removed by the patient, it causes no disruption of normal daily activities. In July this year Photocure announced a global license agreement for Cevira with Asieris Meditech Co., Ltd. Link to Fierce Innovation Award announcement in the 2019 Fierce Innovation Report: Life Sciences Edition Link to Asieris' press release about the award

News and events